Although the genetic defect underlying CDAII was identified more than a decade ago, the mechanism by which SEC23B deficiency results in ineffective erythropoiesis remains unknown, and there are no well-defined therapies for CDAII. Here, SEC23B is linked to Congenital dyserythropoietic anemia type II.